A Comparison of Adherence Rates to Ritonavir and Its Accompanying Protease Inhibitor

The recruitment status of this study is unknown because the information has not been verified recently.

Verified November 2009 by Montefiore Medical Center. Recruitment status was Active, not recruiting

First Received on February 6, 2007. Last Updated on November 4, 2009 History of Changes

Sponsor:	Montefiore Medical Center
Collaborator:	Abbott
Information provided by:	Montefiore Medical Center
ClinicalTrials.gov Identifier:	NCT00432783

Purpose

Pharmacologic boosting of protease inhibitors with ritonavir has become standard practice in antiretroviral therapy. Patients are instructed to take ritonavir at the same time as its accompanying protease inhibitor. However, ritonavir is unpopular with many patients because of its large size and because of the recommended need for refrigeration. This study will test the hypothesis that adherence to ritonavir is inferior to adherence to its accompanying protease inhibitor in patients receiving such therapy.

Condition
HIV Infections

Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	A Comparison of Adherence Rates to Ritonavir (Soft-gel Capsules) and Its Accompanying Protease Inhibitor (PI) in Patients Receiving Ritonavir Boosted PI Regimens

Resource links provided by NLM:

Genetics Home Reference related topics: complement factor I deficiency

MedlinePlus related topics: HIV/AIDS

Drug Information available for: Ritonavir

U.S. FDA Resources

Further study details as provided by Montefiore Medical Center:

Estimated Enrollment:	45
Study Start Date:	June 2006

Detailed Description:

The study staff will employ MEMS caps to prospectively measure adherence to ritonavir and its accompanying protease inhibitor over 24 weeks of follow-up. Paired sample t-tests will be employed to compare adherence to the two agents, and secondary analyses will be conducted to evaluate the chronologic concordance of ritonavir and accompanying protease inhibitor dosing.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Subjects will be recruited from the Montefiore Medical Center Infectious Diseases Clinic who meet eligibility criteria described below.

Criteria

Inclusion Criteria:

HIV infection, age>18 years, receiving therapy with ritonavir-boosted atazanavir or fosamprenavir, willingness to use MEMS caps, willingness to provide informed consent

Exclusion Criteria:

Treatment with any medication that is contraindicated in combination with ritonavir or its accompanying protease inhibitor

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00432783

Locations

United States, New York
Montefiore Medical Center
Bronx, New York, United States, 10467

Sponsors and Collaborators

Montefiore Medical Center

Abbott

Investigators

Principal Investigator:

Jonathan Shuter, MD

Montefiore Medical Center

More Information

No publications provided by Montefiore Medical Center

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Shuter J, Sarlo JA, Rode RA, Zingman BS. Occurrence of selective ritonavir nonadherence and dose-staggering in recipients of boosted HIV-1 protease inhibitor therapy. HIV Clin Trials. 2009 May-Jun;10(3):135-42.

Responsible Party:	Roxann Stubbs/Clinical Science Manager, Abbott Laboratories
ClinicalTrials.gov Identifier:	NCT00432783 History of Changes
Other Study ID Numbers:	06-01-023E
Study First Received:	February 6, 2007
Last Updated:	November 4, 2009
Health Authority:	United States: Institutional Review Board

Keywords provided by Montefiore Medical Center:

HIV, antiretroviral therapy, adherence, ritonavir

Additional relevant MeSH terms:

HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases

Protease Inhibitors
Ritonavir
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
HIV Protease Inhibitors
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on February 09, 2012